[Experience with ebrantil used in patients with resistant arterial hypertension in chronic kidney disease]

To evaluate the clinical efficacy of ebrantil used in patients with resistant arterial hypertension (RAH) in Stage III-V chronic kidney disease (CKD).

Sixty-five patients with Stage III-V CKD and RAH (systolic blood pressure (SBP) 215.7 +/- 4.0 mm Hg and diastolic blood pressure (DBP) 114.6 +/- 2.3 mm Hg) were followed up. The patients received intravenous ebrantil (urapidil) in a dose of 25 mg for 5 days and then were switched to its oral use as 30-60-mg capsules twice daily for 12 weeks.

The intravenous infusion caused a significant fall in SBP and DBP by 23.6 and 16.7%, respectively, within 60-90 min. A steady-state antihypertensive effect was achieved on days 5-7 (SBP and DBP was lowered to 146.8 +/- 6.1 and 95.6 +/- 5.3 mm Hg, respectively; p < 0.05). After 12 weeks of the therapy, SBP was 144.4 +/- 6.3 mm Hg and DBP was 93.3 +/- 4.1 mm Hg (p < 0.05).

The use of ebrantil in patients with CKD and RAH produces an effective BP without marked adverse reactions.